
- | Revolo Biotherapeutics
Get to Know Jonathan Rigby, Group CEO of Revolo Biotherapeutics
BioSpace recently spoke with Jonathan Rigby, Group CEO of Revolo Biotherapeutics, a biotherapeutic company working to revolutionize the treatment of autoimmune and allergic diseases by achieving superior long-term disease remission through resetting the immune system.

- | Scynexis
Novel antifungal effective against vulvovaginal candidiasis in phase 3 trials
Scynexis announced in October that it submitted a new drug application to the FDA for ibrexafungerp for the treatment of vulvovaginal candidiasis. The target action date is set for June 1, 2021. According to the company’s website, another phase 3 trial investigating the efficacy of ibrexafungerp in preventing recurrent vulvovaginal candidiasis is ongoing.

- | Leyden Labs
Despite Many Candidates, Covid-19 Treatments Lag Behind Vaccines
A similar approach—a broad-spectrum antiviral in the form of a nasal spray—has been taken by Leyden Labs in the Netherlands, who recently struck a deal for a €40M Series A funding round to advance its product.

- | Vaxart
Next Generation of Covid-19 Vaccines Could Be Pill or Spray
The next generation of Covid-19 vaccines in development could come as a pill or a nasal spray and be easier to store and transport than the current handful of shots that form the backbone of the world-wide vaccination effort.

- | Vaxart
COVID Innovations: Vaccines for Variants, Drone Deliveries, Print-Your-Own Shots, and More
Vaxart is among the first to take an oral COVID-19 vaccine into the clinic. “Making the vaccine is only part of the problem,” says CSO and founder Sean Tucker. “The rate-limiting step will be how fast can you put it in people’s arms.”

- | Fore Biotherapeutics
High MAPK Activity May Predict MEK Inhibitor Benefit for RAS-Mutated Cancer Patients, Study Finds
By measuring the functional MAPK activity of different RAS mutations, researchers have developed a method they believe could help identify patients with RAS-mutated cancers likely to benefit from MEK inhibitors like trametinib (Novartis’ Mekinist).

- | Palisade Bio
Palisade Bio CEO Tom Hallam Discusses Gastrointestinal Therapeutics
The CEO of Palisade Bio, Tom Hallam, says that the biopharma company is focused on gastrointestinal therapeutics. One of its drug candidates has shown that it can reduce hospital stays following surgery. PALI was formed from a merger between Leading BioSciences and Seneca Biopharma. The stock began trading on the Nasdaq today.

- | Celularity
Celularity: Productizing Placental-Derived Stem Cells for Any Patient
Celularity is a clinical-stage biotechnology company focusing on the next evolution in cellular medicine by developing off-the-shelf placenta-derived allogeneic cell therapies, including genetically modified natural killer (NK) cells and T cells engineered with a chimeric antigen receptor (CAR-T cells) that target indications across cancer as well as infectious and degenerative diseases . . .